dc.contributor.authors |
Eskiler, GG; Deveci, AO; Bilir, C; Kaleli, S; |
|
dc.date.accessioned |
2020-02-27T07:23:01Z |
|
dc.date.available |
2020-02-27T07:23:01Z |
|
dc.date.issued |
2019 |
|
dc.identifier.citation |
Eskiler, GG; Deveci, AO; Bilir, C; Kaleli, S; (2019). Synergistic Effects of Nobiletin and Sorafenib Combination on Metastatic Prostate Cancer Cells. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 71, 1312-1299 |
|
dc.identifier.issn |
0163-5581 |
|
dc.identifier.uri |
https://doi.org/10.1080/01635581.2019.1601237 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/65637 |
|
dc.description.abstract |
Objective: Herein we, for the first time, investigated a potential synergistic effect of nobiletin (NOB) and sorafenib (SOR) on PC-3 prostate cancer and HUVEC control cell lines.Methods: In order to determine the cytotoxic and apoptotic effects of the combination of NOB and SOR, WST-1, Annexin V, and cell cycle analysis were performed. The potential molecular mechanism of apoptotic cell death was assessed by Bax, Bcl-2, CCDN1, Rb1, and CDKN1A gene expression and acridine orange (AO) and DAPI staining.Results: Our results indicated that NOB and SOR combination had a significant inhibitory effect on the viability of PC-3 cells with less toxicity on HUVEC cells than SOR alone (P?<?0.01). NOB and SOR combination significantly caused much more apoptotic cell death and cell cycle arrest at G0/G1 phase by up-regulation of Bax, Rb1, and CDKN1A levels in PC-3 cells (P?<?0.01). Therefore, strong synergistic effects between NOB and SOR were analyzed (CI < 1).Conclusion: NOB and SOR combination was more effective than SOR and NOB alone and reduced the exposure time for SOR and NOB in PC-3 cells. Combination strategy is a therapeutic potential to improve efficacy and reduce side-effect of SOR for the treatment of metastatic prostate cancer cells. |
|
dc.language |
English |
|
dc.publisher |
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD |
|
dc.subject |
Nutrition & Dietetics |
|
dc.title |
Synergistic Effects of Nobiletin and Sorafenib Combination on Metastatic Prostate Cancer Cells |
|
dc.type |
Article |
|
dc.identifier.volume |
71 |
|
dc.identifier.startpage |
1299 |
|
dc.identifier.endpage |
1312 |
|
dc.contributor.department |
Sakarya Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri Bölümü |
|
dc.contributor.saüauthor |
Güney Eskiler, Gamze |
|
dc.contributor.saüauthor |
Deveci Özkan, Asuman |
|
dc.contributor.saüauthor |
Bilir, Cemil |
|
dc.contributor.saüauthor |
Kaleli, Süleyman |
|
dc.relation.journal |
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL |
|
dc.identifier.wos |
WOS:000491428400009 |
|
dc.identifier.doi |
10.1080/01635581.2019.1601237 |
|
dc.identifier.eissn |
1532-7914 |
|
dc.contributor.author |
Güney Eskiler, Gamze |
|
dc.contributor.author |
Deveci Özkan, Asuman |
|
dc.contributor.author |
Bilir, Cemil |
|
dc.contributor.author |
Kaleli, Süleyman |
|